Drug General Information (ID: DDIPR4TYDE)
Drug Name			Dexrazoxane		Drug Info		Doxorubicin		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antineoplastics				Antineoplastics
Structure

Mechanism of Dexrazoxane-Doxorubicin Interaction (Severity Level: Moderate)
Attenuated pharmacological effects (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Dexrazoxane				Doxorubicin
Mechanism		Reduce therapeutic efficacy of doxorubicin				Doxorubicin
Key Mechanism Factor 1
		Factor Name		Pharmacodynamics
		Factor Description		Reduced pharmacological effects leading to insufficient efficacy and/or treatment failure.
Mechanism Description		Attenuated pharmacological effects of  Dexrazoxane when combined with Doxorubicin

Recommended Action
Management		When used as a cardioprotectant, dexrazoxane should not be administered at the initiation of doxorubicin-containing chemotherapy regimens. Dexrazoxane is indicated for reduction of the risk and severity of doxorubicin-induced cardiomyopathy in patients who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Product Information. Adriamycin PFS (doxorubicin). Pharmacia and Upjohn, Kalamazoo, MI.
3	Product Information. Zinecard (dexrazoxane). Pfizer U.S. Pharmaceuticals Group, New York, NY.